Your SlideShare is downloading. ×
Update on New CSR Realignments Basic Oncology and Bioengineering
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Update on New CSR Realignments Basic Oncology and Bioengineering

418

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
418
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. PEER REVIEW ADVISORY COMMITTEE Update on New CSR Realignments Basic Oncology and Bioengineering Don Schneider National Institutes of Health U.S. Department of Health and Human Services February 1, 2010
  • 2. Continuous evolution/alignment of study sections is necessary
    • Science changes
    • CSR is committed to assessment
    • Study section size matters –
    • too small/too large
    • [Fewer than 50 applications
    • Is a problem]
  • 3. Three goals to consider
    • Look at recent reorganizations
    • Examine proposed guideline adjustments for Oncology 1 – Basic Translational (OBT) IRG
    • Re-examine Microscopic Imaging study section
  • 4. Cell Biology merged study sections
    • 2009/05 2010/05
    • Cell Structure Nuclear & Cytoplasmic
    • & Function 41 Struct, Functn, & Dynam
    • Nuclear Dynam 67
    • & Transport 45
    • Cellular Signaling Cellular Signaling
    • & Regulatory & Regulatory
    • Systems 58 Systems 84
    • Subtotal 144 151 applctns
  • 5. Digestv, Kidney, & Urologcl Sys merged study sections
    • 2009/05 2010/05
    • Gastrointestinal
    • Cell & Molecular
    • Biology 41
    • Gastrointestinal Gastrointestinal
    • Mucosal Mucosal
    • Pathobiology 53 Pathobiology 56
    • Hepatobiliary Hepatobiliary
    • Pathophysiology 64 Pathophysiology 78
    • Clinical & Clinical,
    • Integrative Integrative
    • Gastrointestinal & Molecular
    • Pathobiology 46 Gastroenterology 68
    • Subtotal 204 202
  • 6. Bioengineering merged panels
    • 2009/05 2010/05
    • Biodata Management Biodata Management
    • & Analysis 40 & Analysis 88
    • SEP 28
    • Modeling & Analysis Modeling & Analysis
    • Of Biological Of Biological
    • Systems 39 Systems 72
    • Microscopic Microscopic
    • Imaging 20 Imaging 27
    • Subtotal 127 187
  • 7. Interim analysis of realignments is positive
    • Workloads improve (except Micros Imaging)
    • Science and fairness of review are probably better
    • CSR needs metric/tool to measure scientific impact
  • 8. CSR formed five review divisions, January 2009 Translational and Clinical Sciences Cardiovascular and Respiratory Sciences Surgical Sciences, Biomedical Imaging and Bioengineering Musculoskeletal, Oral & Skin Sciences Oncology: Translational Clinical Vascular and Hematology Physiological and Pathological Sciences Endocrinology, Metabolism, Nutrition & Reproductive Sciences Immunology Infectious Diseases & Microbiology Digestive, Kidney & Urological Systems Neuroscience, Development and Aging Brain Disorders & Clinical Neuroscience Molecular, Cellular & Developmental Neuroscience Integrative, Functional & Cognitive Neuroscience Emerging Technologies & Training in Neuroscience Biology of Development & Aging Biobehavioral & Behavioral Processes Risk, Prevention& Health Behavior Population Sciences & Epidemiology Healthcare Delivery & Methodologies AIDS & AIDS Related Research AIDS, Behavioral and Population Sciences Basic and Integrative Biological Sciences Biological Chemistry & Macromolecular Biophysics Bioengineering Sciences & Technologies Genes, Genomes & Genetics Oncology: Basic Translational Cell Biology Interdisciplinary Molecular Sciences & Training
  • 9. Oncology 1 – Basic & Translational IRG was established and reviewed
    • Split ONC to form OBT & OTC January 2009
    • Collected feedback from reviewers two cycles  (October and February meetings)
    • Discussed feedback with Chairs (Chief and DD)
    • Reviewed by CSR Director et al September 23, 2009
    • [Chief – Cathleen Cooper]
  • 10. Realignments are proposed for OBT study sections
    • For emerging trends, clarity of scientific scope, and workload balance, guideline adjustments are proposed:
    • Cancer Molecular Pathology study section (CAMP) –about 110 applications a cycle; focuses on oncogenes and tumor suppressors; move telomeres and epigenomics
    • Cancer Genetics study section (CG) – about 75 applications a cycle; focuses on chromosomal integrity and stability; add telomeres and epigenomics (would fit well)
    • Cancer Etiology study section (CE) – about 90 applications a cycle; focuses on DNA repair and environmental carcinogenesis; move epigenomics unless focus is environmental
    • Estimated result: about 95, 90, and 90 applications
  • 11. Bioengineering Sciences and Technologies IRG was formed in 2004
    • Regular Study Sections
    • Biodata Management and Analysis (BDMA)
    • Biomaterials and Biointerfaces (BMBI)
    • Gene and Drug Delivery Systems (GDD)
    • Instrumentation Systems and Development (ISD)
    • Modeling and Analysis of Biological Systems (MABS)
    • Microscopic Imaging (MI)
    • Nanotechnology (NANO)
    • [Chief – George Chacko]
  • 12. Steps to realign were taken a year ago
    • Original study sections were hybrids in that R01s and R43s were reviewed together – no longer possible
    • BDMA & MI were small, about 50 applications each
    • Via Working Group and PRAC, BDMA was combined with a software SEP and scope of MI was expanded
  • 13. 2009 Realignment worked for BDMA, not for MI
  • 14. Microscopic Imaging and Spectroscopy
    • The study section focuses on review of applications on techniques and instrumentation for microscopic visualization of molecules, organelles, and model systems
    • Development and improvement of microscopic imaging and spectroscopy
    • Development of imaging tools/software
    • Image acquisition and analysis, including single particle
  • 15. Instrumentation Systems and Development shares interests with Microscopic Imaging
    • Optical and spectroscopic instrumentation
    • Microfabrication
    • Automation and integration
    • Sensing of single cells
  • 16. MIS, ISD, & EBT share interests
    • Microscopic Imaging and Spectroscopy, in BST, focus is to develop techniques to visualize molecules, organelles, and cells
    • Instrumentation and Systems Development, in BST, focus is to develop instrumentation for biological research
    • Enabling Bioanalytical and Biophysical Technologies, in BCMB, focus is development of bioanalytical tools to probe molecules
  • 17. Options presented to Working Group
    • [Working within the Bioengineering IRG]
    • Terminate MIS
    • Merge MIS with ISD
    • Expand the scope of MIS
  • 18. Bioengineering Working Group #2 met January 2010
    • ROSTER
    • Wah Chiu, PhD (Baylor College of Medicine)
    • Robert M Dickson, PhD (Georgia Institute of Technology)
    • Michael Gilson, MD, PhD (University of Maryland)
    • Enrico Gratton, PhD (University of California Irvine)
    • Jerome Mertz, PhD (Boston University)
    • Stephen C Miller, PhD (University of Massachusetts Worcester)
    • Amy Palmer, PhD (University of Colorado Boulder)
    • Peter Sorger, PhD (Massachusetts Institute of Technology)
    • Shankar Subramaniam, PhD (University of California San Diego)
    • Stephen Wong, PhD (Cornell University Weill)
    • Xiaowei Zhuang, PhD (Harvard University)
    • NIH: James Deatherage, PhD (NIGMS); Catherine Lewis, PhD (NIGMS); George Chacko, PhD (CSR); Don Schneider, PhD (CSR)
  • 19. Working Group Expressed Preferences
    • Terminate Microscopic Imaging - WG least enthusiasm, integrated basic imaging panel has value, will grow
    • Merge MIS, principally with Instrumentation and Systems Development - WG medium enthusiasm
    • Expand scope and continue Microscopic Imaging - WG considerable enthusiasm
  • 20. Should MI be continued?
    • Element of “Been there, done that”
    • Related issues
    • - EBT study section
    • - IMST IRG
  • 21. CSR created Interdisciplinary Molecular Sciences & Training IRG January 2009
    • IMST uses SEPs to review all fellowship and small business applications for Basic & Integrative Biological Sciences (basic oncology, bio-chemistry/biophysics, bioengineering, cell biology, and genetics)
    • IMST uses SEPs to review interdisciplinary special applications, e.g., some P01s, P41s, and S10s
    • IMST was recently chartered, with understanding that it would form a regular, chartered study section
    • [Chief – Ross Shonat]
  • 22. Taking a bolder, broader view
    • EBT averages about 60 applications a round
    • MI averages about 25 applications a round
    • EBT and MI have complementary interests
    • IMST IRG needs a chartered study section
    • 25 + 60 = 85, close to ideal
    • Create EBIT, Enabling Bioanalytical and Imaging Technologies
  • 23. PRAC input sought
    • Oncology 1 – Basic Translational IRG (OBT)
    • Move telomeres and epigenomics from Cancer Molecular Pathology to Cancer Genetics
    • Move some epigenomics from Cancer Etiology to Cancer Genetics
    • Microscopic Imaging and Spectroscopy
    • Allow more time for growth, OR
    • Merge with Enabling Bioanalytical and Biophysical Technologies and move to Interdisciplinary Molecular Sciences and Training IRG
  • 24.
    • Discussion

×